Phokaewvarangkul Onanong, Kantachadvanich Nithinan, Buranasrikul Vijittra, Sanyawut Kanyawat, Phumphid Saisamorn, Anan Chanawat, Bhidayasiri Roongroj
Chulalongkorn Centre of Excellence for Parkinson's Disease & Related Disorders, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
The Academy of Science, The Royal Science of Thailand, Bangkok, Thailand.
Front Neurol. 2024 Apr 5;15:1379459. doi: 10.3389/fneur.2024.1379459. eCollection 2024.
Apomorphine, a potent dopamine agonist, is a therapeutic option for patients with Parkinson's disease and motor fluctuations. However, the adoption of and adherence to this therapy have been limited by the need for complex delivery devices and specialized care as well as resource consumption, posing challenges for new physicians. Thailand is a unique example of a developing nation that has successfully implemented and continued the use of this therapy by employing cooperative technology that has dramatically enhanced apomorphine delivery services.
Establishing apomorphine delivery services requires significant resources and step-by-step solutions. We began our services by implementing various strategies in three chronological stages: the initial stage (2013-2015), intermediate stage (2016-2019), and current stage (2020-present), each presenting unique challenges. Together, we also implemented a proposed set of five mottos to strengthen our apomorphine delivery service. Using additive technology, we developed a patient registry platform that combined electronic data acquisition, video and remote monitoring using wearable sensors, and in-house mobile applications to support our service.
At the initial stage, we assembled a team to enhance the efficacy and confirm the safety of apomorphine treatment in our hospital. At the intermediate stage, we expanded our apomorphine delivery services beyond just the patients at our hospital. We supported other hospitals in Thailand in setting up their own apomorphine services by educating both physicians and nurses regarding apomorphine therapy. With this educational undertaking, increased apomorphine-related knowledge among medical professionals, and a greater number of hospitals providing apomorphine services, an increasing number of patients were administered apomorphine in subsequent years. Currently, we are providing effective apomorphine delivery to improve patient outcomes and are seamlessly integrating technology into clinical practice. Incorporating integrative technologies in our apomorphine delivery program yielded positive results in data collection and support throughout patient care, in tracking patients' statuses, in the long-term use of this treatment, and in increasing medication adherence rates.
This perspective paper describes how technology can help provide supportive healthcare services in resource-constrained environments, such as in Thailand, offering a step-by-step approach to overcoming several limitations. The valuable insights from our 10-year journey in successfully integrating technology into apomorphine delivery services can benefit new physicians seeking to replicate our success.
阿扑吗啡是一种强效多巴胺激动剂,是帕金森病及运动波动患者的一种治疗选择。然而,由于需要复杂的给药装置、专业护理以及资源消耗,这种治疗方法的采用和依从性受到限制,给新医生带来了挑战。泰国是发展中国家成功实施并持续使用这种治疗方法的一个独特例子,该国采用了合作技术,极大地改善了阿扑吗啡给药服务。
建立阿扑吗啡给药服务需要大量资源和循序渐进的解决方案。我们通过在三个按时间顺序排列的阶段实施各种策略来开展服务:初始阶段(2013 - 2015年)、中期阶段(2016 - 2019年)和当前阶段(2020年至今),每个阶段都有独特的挑战。我们还共同实施了一套提议的五条座右铭,以加强我们的阿扑吗啡给药服务。利用附加技术,我们开发了一个患者登记平台,该平台结合了电子数据采集、使用可穿戴传感器的视频和远程监测以及内部移动应用程序来支持我们的服务。
在初始阶段,我们组建了一个团队,以提高阿扑吗啡治疗在我院的疗效并确认其安全性。在中期阶段,我们将阿扑吗啡给药服务扩展到我院以外的患者。我们通过对医生和护士进行阿扑吗啡治疗方面的教育,支持泰国其他医院建立自己的阿扑吗啡服务。通过这项教育工作,医疗专业人员中与阿扑吗啡相关的知识增加了,提供阿扑吗啡服务的医院数量增多了,在随后几年中接受阿扑吗啡治疗的患者数量也增加了。目前,我们正在提供有效的阿扑吗啡给药,以改善患者预后,并将技术无缝整合到临床实践中。在我们的阿扑吗啡给药计划中纳入综合技术,在整个患者护理过程中的数据收集和支持、跟踪患者状态、这种治疗方法的长期使用以及提高药物依从率方面都产生了积极结果。
这篇观点性文章描述了技术如何有助于在资源有限的环境中(如泰国)提供支持性医疗服务,提供了一种克服多种限制的循序渐进的方法。我们在将技术成功整合到阿扑吗啡给药服务中的10年历程中获得的宝贵见解,可为寻求复制我们成功经验的新医生带来益处。